TCR recognition of MHC class II peptide compexes in multiple sclerosis

多发性硬化症中 MHC II 类肽复合物的 TCR 识别

基本信息

  • 批准号:
    6338632
  • 负责人:
  • 金额:
    $ 21.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-01 至 2001-08-31
  • 项目状态:
    已结题

项目摘要

T cell receptor sequence analysis indicates that myelin specific T cells are expanded in multiple sclerosis (MS) patients, but adequate techniques for the enumerization of antigen-specific T cells in relationship to the disease process are not available. We hypothesize that the frequency of T cells specific for myelin-derived peptides has been greatly underestimated by limiting dilution techniques. Analysis of antigen-specific CD4+ T cells with sensitive techniques will have important implications for understanding the pathogenesis of MS and for developing adequate tools for immune monitoring. The analysis of CD8+ T cells in viral infections has been revolutionized by the creation of tetrameric forms of MHC class I/peptide complexes. Massive expansion of antigen-specific CD8+ T cells has been documented in both acute and chronic viral infections. The introduction of this technology led to the realization that the frequency of antigen specific CD8+ T cells in viral infections had been greatly underestimated. The generation of tetrameric forms of human MHC class II molecules may have a major impact on the investigation of human autoimmune disease. An expression system for soluble HLA-DR2 was previously developed for crystallization of HLA-DR2 with a bound peptide form human myelin basic protein. Based on this expression system, tetramers of HLA-DR2/peptide complexes have been generated with fluorescently labeled streptavidin. These molecules will be used to determine the frequency, activation state and cytokine profile of antigen specific T cells in the cerebrospinal fluid and blood of MS patients with the HLA-DR2 haplotype. The tetramer approach will also be used to generate multivalent TCRs using cDNAs derived from myelin specific T cell clones. MS plaque tissue will be stained with these multivalent TCRs to examine surface expression of HLA-DR2-bound myelin peptides by antigen presenting cells in the target organ.
T细胞受体序列分析表明,髓磷脂特异性T细胞在多发性硬化症(MS)患者中扩增,但与疾病过程相关的抗原特异性T细胞计数的适当技术不可用。我们推测,髓鞘衍生肽特异性T细胞的频率已大大低估了有限稀释技术。用敏感的技术分析抗原特异性CD4 + T细胞将对理解MS的发病机制和开发适当的免疫监测工具具有重要意义。病毒感染中CD8 + T细胞的分析已经通过产生MHC I类/肽复合物的四聚体形式而发生了革命性的变化。在急性和慢性病毒感染中均记录了抗原特异性CD8 + T细胞的大量扩增。这项技术的引入使人们认识到,抗原特异性CD8 + T细胞在病毒感染中的频率被大大低估了。人类MHC II类分子的四聚体形式的产生可能对人类自身免疫性疾病的研究产生重大影响。可溶性HLA-DR 2的表达系统先前被开发用于结晶HLA-DR 2与结合的肽形式的人髓鞘碱性蛋白。基于该表达系统,已经用荧光标记的链霉亲和素产生了HLA-DR 2/肽复合物的四聚体。这些分子将用于确定具有HLA-DR2单倍型的MS患者的脑脊液和血液中抗原特异性T细胞的频率、活化状态和细胞因子谱。四聚体方法也将用于使用源自髓磷脂特异性T细胞克隆的cDNA产生多价TCR。MS斑块组织将用这些多价TCR染色,以检查靶器官中抗原呈递细胞对HLA-DR 2结合的髓鞘肽的表面表达。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kai W Wucherpfennig其他文献

Cracking the code of human T-cell immunity
破解人类 T 细胞免疫的密码
  • DOI:
    10.1038/nbt.2626
  • 发表时间:
    2013-07-09
  • 期刊:
  • 影响因子:
    41.700
  • 作者:
    Christopher J Harvey;Kai W Wucherpfennig
  • 通讯作者:
    Kai W Wucherpfennig
4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine
  • DOI:
    10.1182/blood-2023-182381
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;John G. Clohessy;Sophia Adamia;Kai W Wucherpfennig;Donald Kufe;Jacalyn Rosenblatt;David Avigan
  • 通讯作者:
    David Avigan
Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
  • DOI:
    10.1182/blood-2024-200876
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Prateek Pophali;Giulia Cheloni;Richard M. Stone;Kai W Wucherpfennig;Aric C. Hall;Amir T. Fathi;Lina Bisharat;Emma K Logan;Yiwen Liu;Donna S. Neuberg;Malgorzata McMasters;Jessica Liegel;Jacqueline S. Garcia;Daniel J. DeAngelo;Michele Narcis;Dina Stroopinsky;Pavania Elavalakanar;Ioannis S Vlachos;Ilene A. Galinsky;Jason Pyrdol
  • 通讯作者:
    Jason Pyrdol
Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine
  • DOI:
    10.1182/blood-2024-208563
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;Jonah Lee;John G. Clohessy;Samprity Ankita;Rajeev Relangi;Lina Bisharat;Hazal Toros;Sophia Adamia;Jasper B Lee;Donald Kufe;Kai W Wucherpfennig;Jacalyn Rosenblatt;David Avigan
  • 通讯作者:
    David Avigan

Kai W Wucherpfennig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kai W Wucherpfennig', 18)}}的其他基金

Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
MICA 免疫逃避的治疗靶向 - NKG2D 通路
  • 批准号:
    10380449
  • 财政年份:
    2021
  • 资助金额:
    $ 21.48万
  • 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
  • 批准号:
    10210225
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10029035
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
  • 批准号:
    10210221
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10224146
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10400167
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
  • 批准号:
    10477984
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10668947
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
  • 批准号:
    10684029
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
  • 批准号:
    10684050
  • 财政年份:
    2020
  • 资助金额:
    $ 21.48万
  • 项目类别:

相似海外基金

The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
  • 批准号:
    DP240102905
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23K28188
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
  • 批准号:
    2339172
  • 财政年份:
    2024
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
  • 批准号:
    10577518
  • 财政年份:
    2023
  • 资助金额:
    $ 21.48万
  • 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23H03498
  • 财政年份:
    2023
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
  • 批准号:
    10676407
  • 财政年份:
    2023
  • 资助金额:
    $ 21.48万
  • 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
  • 批准号:
    22KK0277
  • 财政年份:
    2023
  • 资助金额:
    $ 21.48万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
  • 批准号:
    10599584
  • 财政年份:
    2023
  • 资助金额:
    $ 21.48万
  • 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
  • 批准号:
    10530023
  • 财政年份:
    2022
  • 资助金额:
    $ 21.48万
  • 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
  • 批准号:
    10684172
  • 财政年份:
    2022
  • 资助金额:
    $ 21.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了